We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California, Inc. ((PACB - Free Report) )reported first-quarter 2020 earnings per share of a penny against the Zacks Consensus Estimate of a loss of 15 cents. The company had reported a loss of 20 cents in the year-ago quarter.
Revenues totaled $15.6 million, which missed the Zacks Consensus Estimate by 22.4% and fell 4.9% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenues: At this segment, revenues amounted to $12.3 million, down 8.9% from the prior-year quarter’s tally.
Service and Other Revenues: At this segment, revenues came in at $3.3 million, up 13.8% year over year.
Margins
Gross profit in the first quarter was $7.5 million, up 46.3% year over year.Gross margin was 48% of total revenues, expanding 1685 basis points.
Operating expenses totaled $40.2 million, up 14% year over year.
Operating loss came in at $32.7 million, wider than the year-ago quarter’s loss of $30.1 million.
Pacific Biosciences of California Inc Price, Consensus and EPS Surprise
On Jan 2, 2020, Pacific Biosciences and Illumina agreed to terminate their merger agreement, which was announced in 2019.
Our Take
Pacific Biosciences ended the first quarter on a mixed note.The company saw revenue growth in its Service and Other segment. The company continues to gain from its flagship Sequel system. Massive gross margin expansion was also noted in the quarter. Additionally, the company received termination fee from Illumina, which got reflected on the results. On the flip side,the company saw decline in Product revenues. Escalation of operating expenses is another concern.
Zacks Rank and Other Key Picks
Pacific Biosciences currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million outpaced the consensus estimate by 14.6%. The company carries a Zacks Rank #2 at present.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates
Pacific Biosciences of California, Inc. ((PACB - Free Report) ) reported first-quarter 2020 earnings per share of a penny against the Zacks Consensus Estimate of a loss of 15 cents. The company had reported a loss of 20 cents in the year-ago quarter.
Revenues totaled $15.6 million, which missed the Zacks Consensus Estimate by 22.4% and fell 4.9% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenues: At this segment, revenues amounted to $12.3 million, down 8.9% from the prior-year quarter’s tally.
Service and Other Revenues: At this segment, revenues came in at $3.3 million, up 13.8% year over year.
Margins
Gross profit in the first quarter was $7.5 million, up 46.3% year over year.Gross margin was 48% of total revenues, expanding 1685 basis points.
Operating expenses totaled $40.2 million, up 14% year over year.
Operating loss came in at $32.7 million, wider than the year-ago quarter’s loss of $30.1 million.
Pacific Biosciences of California Inc Price, Consensus and EPS Surprise
Pacific Biosciences of California Inc price-consensus-eps-surprise-chart | Pacific Biosciences of California Inc Quote
Merger Termination With Illumina
On Jan 2, 2020, Pacific Biosciences and Illumina agreed to terminate their merger agreement, which was announced in 2019.
Our Take
Pacific Biosciences ended the first quarter on a mixed note.The company saw revenue growth in its Service and Other segment. The company continues to gain from its flagship Sequel system. Massive gross margin expansion was also noted in the quarter. Additionally, the company received termination fee from Illumina, which got reflected on the results. On the flip side,the company saw decline in Product revenues. Escalation of operating expenses is another concern.
Zacks Rank and Other Key Picks
Pacific Biosciences currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million outpaced the consensus estimate by 14.6%. The company carries a Zacks Rank #2 at present.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>